https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — BERLIN — The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic colorectal cancer, a phase…
